Capricor Therapeutics Shares Rose After Clinical Update
The firm reported new data showing its experimental drug slowed motor decline in patients with muscular dystrophy.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you rely on your own interpretation of clinical study results when making investment decisions?
Capricor Therapeutics shares jumped 20 percent in after-hours trading on September 29, 2026, following the release of new clinical trial findings. The company reported that patients switching to its drug Deramiocel experienced a 76 percent slower decline in upper-limb function.
Why it matters
The clinical trial results offer potential hope for patients with Duchenne muscular dystrophy, a condition that causes progressive muscle deterioration. The positive data release significantly altered market sentiment following a 70 percent decline in the company stock year-to-date.
Patients who switched from a placebo to Deramiocel showed a 76 percent reduction in the rate of upper-limb function loss. Additionally, elbow-related motor decline was 66 percent slower in the treated group compared to their previous year on a placebo.
The players
Capricor Therapeutics
This is a biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy and other serious conditions.
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs and biological products.
World Muscle Society
This is an international professional organization that facilitates the exchange of scientific knowledge regarding neuromuscular disorders through its annual congress.
The details
Capricor presented the data from the 24-month Hope-3 extension study at the World Muscle Society congress in Hiroshima. The findings demonstrate that treatment with Deramiocel can significantly slow motor deterioration in patients compared to their initial performance on a placebo.
Timeline
August 2026: Capricor submitted 24-month Hope-3 extension data to the FDA.
September 29, 2026: CAPR shares closed at 8.57 dollars before rising 20 percent after-hours.
September 29 to October 3, 2026: The World Muscle Society congress took place in Hiroshima.
October 3, 2026: The company is scheduled to present data on muscle and cardiac efficacy.
November 22, 2026: The FDA deadline for a decision on the Deramiocel application.
The Tech Race
The development of Deramiocel marks a shift toward specialized genetic and cellular therapies in the race to treat degenerative conditions like muscular dystrophy. This advancement positions Capricor within a competitive biotech landscape focused on moving beyond traditional palliative care toward disease-modifying treatments.
For patients and families navigating Duchenne muscular dystrophy, this data represents a potential new treatment pathway that could extend mobility. Investors in the biotech sector should note that despite the after-hours rally, the stock remains down 70 percent for the year, and analysts estimate only a 40 percent probability of eventual drug approval.
The takeaway
The sharp market movement highlights the high-stakes nature of biotech drug approvals where clinical trial data remains the primary driver of investor confidence. Patients and caregivers should continue to monitor regulatory updates for definitive news on treatment availability.
What happens next
The FDA is expected to announce its regulatory decision regarding the Deramiocel application by the November 22, 2026, deadline.
Further reading
For more on the latest research in the industry, visit the Biotech section.
Live Poll
Do you rely on your own interpretation of clinical study results when making investment decisions?
